Tamoxifen has been reported to be oestrogenic on the lower genital tract. To evaluate its potential positive effect on the endometrium, and consequently early miscarriage and ongoing pregnancy rate, a prospective study was employed in patients for intrauterine insemination who failed to develop an adequate endometrial thickness in a previous ovulatory cycle. Ovarian stimulation was initiated with tamoxifen 40 mg/day from day 3 of the menstrual cycle for 7 days or clomiphene 100 mg/day for 5 days, in combination with 150 IU of human menopausal gonadotrophin on alternate days starting on day 4. Human chorionic gonadotrophin (HCG) was administered when at least one leading follicle was larger than 20 mm. Intrauterine insemination was accomplished 24–36 h after HCG injection and luteal phase supplement was achieved with micronized progesterone 200 mg transvaginally per day. It was found that tamoxifen-treated patients required more stimulation days and used more gonadotrophin, but recruited less follicles larger than 14 mm than clomiphene-treated patients. However, a significantly increased endometrial thickness (Chia-Woei Wang obtained his medical degree from National Taiwan University, Taiwan. Background: Being a selective estrogen receptor inhibitor (SERM) tamoxifen may be used an alternative to clomiphene citrate for ovulation induction in women with anovulatory infertility. Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis. This study was conducted to evaluate the safety and efficacy of tamoxifen as compared to clomiphene citrate in women with primary or secondary anovulatory infertility due to Polycystic Ovarian Syndrome (PCOS). Methods: One hundred women suffering from anovulatory infertility and attending the infertility clinic and were recruited for the study. Williamson JG and Ellis JD The induction of ovulation by tamoxifen. Patients were randomized to receive either clomiphene citrate (100-150 mg) or tamoxifen treatment (40-80 mg). Kettal LM, Roseff SJ, Berga S et al: Hypothalamic-pituitary-ovarian response to clomiphene citrate women with polycystic ovary syndrome. Brown J, Farquhar C, Beck J, Boothroyd C, Proctor M, Hughes E. Eden JA, Place J, Carter GD, Jones J, Alaghband-Zadeh, Pawson ME. Characteristics relating to ovarian risk: Collaborative analysis of 12 US case-control studies. The ovulation was monitored from day 5 to day 9 of menstrual cycle followed up by transvaginal ultrasound from day 11 every alternate day for 10 days. Results: The baseline characteristics of mean age, weight, proportion of patients with primary and secondary infertility and mean duration of infertility were comparable between both the study groups. Clark JH, Markaverich BM: The agonistic-antagonistic properties of clomiphene: A review. Oral anti-estrogen and medical adjuncts for subfertility associated with anovulation. The effect of clomiphene citrate on follicular phase increase in endometrial thickness and uterine volume. Out of 50 patients who received clomiphene citrate, 37 showed successful ovulation (ovulation rate of 64%) and 16 patients conceived (pregnancy rate of 32%). In tamoxifen group 41 women showed successful ovulation (ovulation rate of 82%) and 18 women conceived (pregnancy rate of 36%).
BACKGROUND: Both selective estrogen receptor modulators, tamoxifen and clomiphene have been used for ovulation induction for patients with anovulatory infertility. This meta-analysis sought to compare the effectiveness of tamoxifen to clomiphene for the induction of ovulation and achievement of pregnancy. METHODS: We searched MEDLINE, BIOSIS, Pre MEDLINE, CINAHL, International Pharmaceutical Abstracts, DDSR, ACP Journal Club, DARE and CCTR, along with reference lists and national experts. Inclusion criteria were prospective clinical trials, which compared tamoxifen and clomiphene for ovulation induction in infertile couples with isolated anovulatory infertility. Main outcome measures were ovulation rate and clinical pregnancy rate. Pooled odds ratios were obtained using random effects meta-analysis. After pooling all the trials, the use of tamoxifen or clomiphene citrate resulted in similar ovulation rates [odds ratio (OR) 0.755, 95% confidence interval (CI) 0.513–1.111]. There was no benefit of tamoxifen over clomiphene citrate in achievement of pregnancy per cycle (OR 1.056, 95% CI 0.583–1.912) or per ovulatory cycle (OR 1.162, 95% CI 0.632–2.134). Tamoxifen is the main hormone treatment used for breast cancer in women who haven't yet gone through the menopause. It's sometimes also used to treat post-menopausal women. Tamoxifen can be used in several different ways for breast cancer, depending on the stage of the cancer and what other treatment options are used. Most women take tamoxifen for five years after having surgery, chemotherapy or radiotherapy (or a combination of these) for their breast cancer. The tamoxifen reduces the risk of the cancer coming back and also reduces the risk of getting cancer in the other breast. Some women may take tamoxifen for two or three years and then switch to a different hormonal therapy. Sometimes tamoxifen can be used to help shrink a large tumour before having surgery; for some women this can help avoid having a mastectomy.
Apr 21, 2005. Abstract. BACKGROUND Both selective estrogen receptor modulators, tamoxifen and clomiphene have been used for ovulation induction for. Abstract. BACKGROUND Both selective estrogen receptor modulators, tamoxifen and clomiphene have been used for ovulation induction for patients with anovulator